Barclays raised its rating on Recordati to "equal weight" from "underweight," citing reduced risks from a potential share sale by its largest shareholder. The downgrade previously reflected concerns that private equity firm CVC Capital Partners might offload its stake, creating downward pressure on the stock.

An "equal weight" rating suggests the stock is now seen as fairly valued relative to peers, with the immediate threat of a large block sale diminishing. The analyst move directly addresses the "CVC share overhang," a specific market concern that had weighed on investor sentiment.

This upgrade provides a near-term support signal for the Italian pharmaceutical company's shares. It indicates the market has likely priced in the former selling pressure, removing a key negative catalyst that had previously justified a more cautious stance.